The KIF22 antibody is a crucial tool for studying the kinesin family member 22 (KIF22), a motor protein belonging to the kinesin-4 subfamily. KIF22 plays a key role in mitotic processes, particularly in regulating chromosome alignment and spindle dynamics during cell division. It interacts with microtubules and contributes to their stability and organization, ensuring accurate segregation of genetic material. Dysregulation of KIF22 has been linked to genomic instability and cancer progression, with overexpression observed in malignancies like osteosarcoma, hepatocellular carcinoma, and glioblastoma, where it correlates with poor prognosis and aggressive phenotypes.
KIF22 antibodies are widely used in biomedical research to detect protein expression levels, localization, and functional interactions in cellular and tissue samples. These antibodies are essential for techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Validated for specificity, they help elucidate KIF22's role in tumorigenesis, metastasis, and therapeutic resistance. Recent studies also explore KIF22 as a potential diagnostic biomarker or therapeutic target, particularly in cancers with chromosomal instability. Researchers rely on high-quality KIF22 antibodies to investigate its molecular mechanisms and evaluate its clinical relevance in precision medicine approaches.